You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
News and reporting on colorectal cancer.
The team saw risky mutations in colorectal cancer, polyp, and Lynch syndrome-related genes in almost 4 percent of CRC patients diagnosed at 72 years old, on average.
Researchers focused on candidate genes near expression quantitative trait loci identified by combining cancer susceptibility SNPs and available transcriptomic data.
Biocartis' Idylla called some colorectal cancer samples negative that Sysmex Inostics's OncoBEAM called positive, but the clinical implications may be complex.
The firm believes that physicians can use information from the cell-free DNA analyzed by the assay to determine whether to use anti-EGFR drugs during treatment.
Financial analysts seemed convinced of the long-term advantages of the deal but noted that investors may remain skeptical in the near term.
Exact said it will pay $72 per share for Genomic Health for a total transaction price of $2.8 billion in cash and stock.
The firm claims that its liquid biopsy platform can identify mutations in patient samples at femtogram-level concentrations.
Investigators pooled older and new data from the Prospective Lynch Syndrome Database, tracking outcomes for different mutations across age and gender groups.
The firm will use the funding to begin a validation study of its blood-based test for early detection of colorectal cancer.
In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.
NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.
Politico reports President Donald Trump has signed the $2 trillion coronavirus relief package.
A new analysis finds that peer review improves the quality of preprints just a little bit, according to ScienceInsider.
In PLOS this week: epigenetic drug triggers anti-viral activity, viral diversity among individuals with HIV experiencing virological failure, and more.